{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:40:31Z","timestamp":1792525231353,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Australian Government Research Training Program; and Perron Institute for Neurological and Translational Science"},{"name":"Western Australian State Government\u2019s Future Health and Innovation Fund, Innovation Challenge 2021: Child and Youth Mental Health program"},{"name":"Sarich Family"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pharmacogenetic (PGx) testing to guide antidepressant prescribing is becoming increasingly available. However, its uptake into routine psychiatric practice for young people remains limited due to insufficient youth-specific evidence and uncertainty regarding optimal trial design and outcome selection. This pilot study aimed to evaluate the feasibility of implementing a rigorous triple-blind randomized controlled trial to examine PGx-guided antidepressant treatment compared with treatment-as-usual (TAU) in young Australians with depression. The pharmacoGENEtics in Youth Depression (GENE-YD) study recruited young people aged 16\u201324 years old with major depressive disorder over 13 months, allocating 1:1 to PGx-Guided treatment or TAU. Depressive symptoms and quality-of-life outcomes were measured using rater-administered measures and self-report questionnaires at Baseline and at 6- and 12-weeks follow-up. Feasibility outcomes included recruitment, adherence, attrition, participant satisfaction, and protocol fidelity. Of 73 individuals screened, 55 were eligible and randomized. Baseline data were collected from 39 participants, with 38 completing assessments through Week 12. Adherence to the study protocol and assessment schedule was high, attrition was low, and participant satisfaction was strong. Clinically meaningful improvements were observed, with the PGx-Guided group showing greater reductions in depressive symptom severity, higher rates of treatment response and remission, and improved quality-of-life outcomes compared with TAU. The GENE-YD Study demonstrated that a triple-blind PGx-guided antidepressant trial is feasible and acceptable in young people with depression, with preliminary indications of clinical benefit. These findings support the inclusion of broader patient-centered outcomes beyond symptom change and will inform methodological refinements for future fully powered youth-specific PGx trials.<\/jats:p>","DOI":"10.1038\/s41398-026-04321-x","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:45:19Z","timestamp":1785581119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The pharmacogGENEtics in Youth Depression (GENE-YD) study for personalizing antidepressant pharmacotherapy for young Western Australians \u2013 A feasibility study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-5466","authenticated-orcid":false,"given":"Bradley","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Miljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0404-9018","authenticated-orcid":false,"given":"Susanne","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette T.","family":"Majda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khan R. L.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Woodland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kyron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3428-940X","authenticated-orcid":false,"given":"Svetlana","family":"Baltic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanna E. L.","family":"Temple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Anthony","family":"Akkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2852-7923","authenticated-orcid":false,"given":"Sean D.","family":"Hood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3413-4229","authenticated-orcid":false,"given":"Jennifer","family":"Rodger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"4321_CR1","volume-title":"Child and adolescent mental health and educational outcomes. An analysis of educational outcomes from Young Minds Matter: the second Australian child and adolescent survey of mental health and wellbeing","author":"B Goodsell","year":"2017","unstructured":"Goodsell B, Lawrence D, Ainley J, Sawyer M, Zubrick S, Maratos J Child and adolescent mental health and educational outcomes. An analysis of educational outcomes from Young Minds Matter: the second Australian child and adolescent survey of mental health and wellbeing. Perth: Graduate School of Education, The University of Western Australia; 2017."},{"key":"4321_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jadohealth.2012.12.016","volume":"52","author":"K Naicker","year":"2013","unstructured":"Naicker K, Galambos NL, Zeng Y, Senthilselvan A, Colman I. Social, demographic, and health outcomes in the 10 years following adolescent depression. J Adolesc Health. 2013;52:533\u20138.","journal-title":"J Adolesc Health"},{"key":"4321_CR3","first-page":"49","volume":"57","author":"J de Oliveira Costa","year":"2023","unstructured":"de Oliveira Costa J, Gillies MB, Schaffer AL, Peiris D, Zoega H, Pearson SA. Changes in antidepressant use in Australia: a nationwide analysis (2015\u20132021). ANZJP. 2023;57:49\u201357.","journal-title":"ANZJP"},{"key":"4321_CR4","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1001\/jama.299.8.901","volume":"299","author":"D Brent","year":"2008","unstructured":"Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008;299:901\u201313.","journal-title":"JAMA"},{"key":"4321_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/archpsyc.64.10.1132","volume":"64","author":"JS March","year":"2007","unstructured":"March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007;64:1132\u201343.","journal-title":"Arch Gen Psychiatry"},{"key":"4321_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-0844-3","volume":"16","author":"K Gibson","year":"2016","unstructured":"Gibson K, Cartwright C, Read J. \u2018In my life antidepressants have been\u2026\u2019: a qualitative analysis of users\u2019 diverse experiences with antidepressants. BMC Psychiatry. 2016;16:135.","journal-title":"BMC Psychiatry"},{"key":"4321_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.31887\/DCNS.2009.11.4\/afleuchter","volume":"11","author":"AF Leuchter","year":"2009","unstructured":"Leuchter AF, Cook IA, Hunter AM, Korb AS. A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin Neurosci. 2009;11:435\u201346.","journal-title":"Dialogues Clin Neurosci"},{"key":"4321_CR8","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.jad.2021.09.034","volume":"295","author":"P Lampela","year":"2021","unstructured":"Lampela P, Tanskanen A, L\u00e4hteenvuo M, Tiihonen J, Taipale H. Switches and early discontinuations of antidepressant medication in young adults with depression. J Affect Disord. 2021;295:1474\u201381.","journal-title":"J Affect Disord"},{"key":"4321_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/phar.2767","volume":"43","author":"JR Strawn","year":"2023","unstructured":"Strawn JR, Mills JA, Poweleit EA, Ramsey LB, Croarkin PE. Adverse effects of antidepressant medications and their management in children and adolescents. Pharmacotherapy. 2023;43:675\u201390.","journal-title":"Pharmacotherapy"},{"key":"4321_CR10","doi-asserted-by":"publisher","unstructured":"Newbound CN, Roberts B, Cooper Z, Rodger J, Hood SD, Hryniewicki J, et al. Real-world applications of pharmacogenomics in paediatrics. J Paediatr Child Health. 2025; https:\/\/doi.org\/10.1111\/jpc.70239.","DOI":"10.1111\/jpc.70239"},{"key":"4321_CR11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jaac.2020.08.006","volume":"60","author":"LB Ramsey","year":"2021","unstructured":"Ramsey LB, Namerow LB, Bishop JR, Hicks JK, Bousman C, Croarkin PE, et al. Thoughtful clinical use of pharmacogenetics in child and adolescent psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2021;60:660\u20134.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"4321_CR12","first-page":"40","volume":"48","author":"AM Wehry","year":"2018","unstructured":"Wehry AM, Ramsey L, Dulemba SE, Mossman SA, Strawn JR. Pharmacogenomic testing in child and adolescent psychiatry: an evidence-based review. Curr Probl Pediatr Adolesc Health Care. 2018;48:40\u20139.","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"4321_CR13","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.1017\/S0033291723002817","volume":"53","author":"CA Bousman","year":"2023","unstructured":"Bousman CA, Maruf AA, Marques DF, Brown LC, M\u00fcller DJ. The emergence, implementation, and future growth of pharmacogenomics in psychiatry: a narrative review. Psychol Med. 2023;53:7983\u201393.","journal-title":"Psychol Med"},{"key":"4321_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1267294","volume":"14","author":"B Roberts","year":"2023","unstructured":"Roberts B, Cooper Z, Lu S, Stanley S, Majda BT, Collins KRL, et al. Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review. Front Pharmacol. 2023;14:1267294.","journal-title":"Front Pharmacol"},{"key":"4321_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1276410","volume":"15","author":"KG Tesfamicael","year":"2024","unstructured":"Tesfamicael KG, Zhao L, Fern\u00e1ndez-Rodr\u00edguez R, Adelson DL, Musker M, Polasek TM, et al. Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis. Front Psychiatry. 2024;15:1276410.","journal-title":"Front Psychiatry"},{"key":"4321_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaac.2021.03.011","volume":"61","author":"JL Vande Voort","year":"2022","unstructured":"Vande Voort JL, Orth SS, Shekunov J, Romanowicz M, Geske JR, Ward JA, et al. A randomized controlled trial of combinatorial pharmacogenetics testing in adolescent depression. J Am Acad Child Adolesc Psychiatry. 2022;61:46\u201355.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"4321_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1089\/cap.2023.0043","volume":"34","author":"S Nooraeen","year":"2024","unstructured":"Nooraeen S, Croarkin PE, Geske JR, Shekunov J, Orth SS, Romanowicz M, et al. High probability of gene-drug interactions associated with medication side effects in adolescent depression: results from a randomized controlled trial of pharmacogenetic testing. J Child Adolesc Psychopharmacol. 2024;34:28\u201333.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"4321_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.121065","volume":"398","author":"L Li","year":"2026","unstructured":"Li L, Xu L, Wang Q, Sun Z, Han Y, Zheng L, et al. Effectiveness of pharmacogenomic testing across age groups for depressive disorder treatment and its age-dependent effects on cognitive function: a randomized controlled trial. J Affect Disord. 2026;398:121065.","journal-title":"J Affect Disord"},{"key":"4321_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.euroneuro.2025.08.003","volume":"100","author":"NE Fares-Otero","year":"2025","unstructured":"Fares-Otero NE, Budde M, Laatsch J, Harrer M, Pelgrim T, Philipsen A, et al. Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: a systematic review and meta-analysis. Eur Neuropsychopharmacology. 2025;100:13\u201323.","journal-title":"Eur Neuropsychopharmacology"},{"key":"4321_CR20","doi-asserted-by":"publisher","first-page":"e103644","DOI":"10.1136\/bmjopen-2025-103644","volume":"15","author":"B Roberts","year":"2025","unstructured":"Roberts B, Cooper Z, Miljevic A, Stanley SH, Majda BT, Collins KRL, et al. PharmacoGENEtics in Youth Depression (GENE-YD) Study protocol: a pilot triple-blinded randomised controlled trial using pharmacogenetics to tailor antidepressant treatment in young Australians. BMJ Open. 2025;15:e103644.","journal-title":"BMJ Open"},{"key":"4321_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/0004867420979353","volume":"55","author":"GS Malhi","year":"2021","unstructured":"Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, et al. The 2020 royal Australian and New Zealand college of psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2021;55:7\u2013117.","journal-title":"Aust N Z J Psychiatry"},{"key":"4321_CR22","unstructured":"Gene S. RosaMind [Internet]. 2025 [cited 2026 Jan 22]. Available from: https:\/\/gene-s.com\/rosamind\/."},{"key":"4321_CR23","doi-asserted-by":"publisher","first-page":"e13848","DOI":"10.2196\/13848","volume":"8","author":"B Manzor Mitrzyk","year":"2019","unstructured":"Manzor Mitrzyk B, Kadri R, Farris KB, Ellingrod VL, Klinkman MS, Ruffin Iv MT, et al. Using pharmacogenomic testing in primary care: protocol for a pilot randomized controlled study. JMIR Res Protoc. 2019;8:e13848.","journal-title":"JMIR Res Protoc"},{"key":"4321_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/MLR.0000000000001664","volume":"60","author":"JA Teresi","year":"2022","unstructured":"Teresi JA, Yu X, Stewart AL, Hays RD. Guidelines for designing and evaluating feasibility pilot studies. Med Care. 2022;60:95\u2013103.","journal-title":"Med Care"},{"key":"4321_CR25","doi-asserted-by":"publisher","first-page":"i5239","DOI":"10.1136\/bmj.i5239","volume":"355","author":"SM Eldridge","year":"2016","unstructured":"Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.","journal-title":"BMJ"},{"key":"4321_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j..2002.384.doc.x","volume":"10","author":"GA Lancaster","year":"2004","unstructured":"Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004;10:307\u201312.","journal-title":"J Eval Clin Pract"},{"key":"4321_CR27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jpsychires.2010.10.008","volume":"45","author":"AC Leon","year":"2011","unstructured":"Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2011;45:626\u20139.","journal-title":"J Psychiatr Res"},{"key":"4321_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","volume":"401","author":"JJ Swen","year":"2023","unstructured":"Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401:347\u201356.","journal-title":"Lancet"},{"key":"4321_CR29","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/00004583-200210000-00010","volume":"41","author":"GJ Emslie","year":"2002","unstructured":"Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41:1205\u201315.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"4321_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05119-6","volume":"22","author":"L Niemeyer","year":"2021","unstructured":"Niemeyer L, Mechler K, Buitelaar J, Durston S, Gooskens B, Oranje B, et al. \u201cInclude me if you can\u201d\u2014reasons for low enrollment of pediatric patients in a psychopharmacological trial. Trials. 2021;22:178.","journal-title":"Trials"},{"key":"4321_CR31","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.3390\/jcm12062307","volume":"12","author":"D Kilicel","year":"2023","unstructured":"Kilicel D, De Crescenzo F, Pontrelli G, Armando M. Participant recruitment issues in child and adolescent psychiatry clinical trials with a focus on prevention programs: a meta-analytic review of the literature. J Clin Med. 2023;12:2307.","journal-title":"J Clin Med"},{"key":"4321_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-025-13580-1","volume":"25","author":"Z Cooper","year":"2025","unstructured":"Cooper Z, Roberts B, Landery G, Woodland S, Collins KRL, Majda BT, et al. Exploring the perspectives of young adults on mental healthcare and systemic health, education, and social challenges in Australia: a qualitative study. BMC Health Serv Res. 2025;25:1402.","journal-title":"BMC Health Serv Res"},{"key":"4321_CR33","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2105\/AJPH.89.9.1322","volume":"89","author":"RE Glasgow","year":"1999","unstructured":"Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89:1322\u20137.","journal-title":"Am J Public Health"},{"key":"4321_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jclinepi.2013.08.015","volume":"67","author":"J McCambridge","year":"2014","unstructured":"McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014;67:267\u201377.","journal-title":"J Clin Epidemiol"},{"key":"4321_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/1060028014522982","volume":"48","author":"E Tommelein","year":"2014","unstructured":"Tommelein E, Mehuys E, Van Tongelen I, Brusselle G, Boussery K. Accuracy of the Medication Adherence Report Scale (MARS-5) as a quantitative measure of adherence to inhalation medication in patients with COPD. Ann Pharmacother. 2014;48:589\u201395.","journal-title":"Ann Pharmacother"},{"key":"4321_CR36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0005-7967(94)00075-U","volume":"33","author":"PF Lovibond","year":"1995","unstructured":"Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995;33:335\u201343.","journal-title":"Behav Res Ther"},{"key":"4321_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10862-014-9461-y","volume":"37","author":"RB Weiss","year":"2015","unstructured":"Weiss RB, Aderka IM, Lee J, Beard C, Bj\u00f6rgvinsson T. A comparison of three brief depression measures in an acute psychiatric population: CES-D-10, QIDS-SR, and DASS-21-DEP. J Psychopathology Behav Assess. 2015;37:217\u201330.","journal-title":"J Psychopathology Behav Assess"},{"key":"4321_CR38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/da.23113","volume":"38","author":"S Saha","year":"2021","unstructured":"Saha S, Lim CCW, Cannon DL, Burton L, Bremner M, Cosgrove P, et al. Co-morbidity between mood and anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2021;38:286\u2013306.","journal-title":"Depress Anxiety"},{"key":"4321_CR39","first-page":"293","volume":"17","author":"J Garber","year":"2010","unstructured":"Garber J, Weersing VR. Comorbidity of anxiety and depression in youth: implications for treatment and prevention. Clin Psychol. 2010;17:293\u2013306.","journal-title":"Clin Psychol"},{"key":"4321_CR40","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.psc.2024.04.012","volume":"47","author":"KB O\u2019Leary","year":"2024","unstructured":"O\u2019Leary KB, Khan JS. Pharmacotherapy for anxiety disorders. Psychiatr Clin North Am. 2024;47:689\u2013709.","journal-title":"Psychiatr Clin North Am"},{"key":"4321_CR41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S2215-0366(20)30137-1","volume":"7","author":"X Zhou","year":"2020","unstructured":"Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:581\u2013601.","journal-title":"Lancet Psychiatry"},{"key":"4321_CR42","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1017\/S1461145712001265","volume":"17","author":"CM D\u00edaz-Caneja","year":"2014","unstructured":"D\u00edaz-Caneja CM, Espliego A, Parellada M, Arango C, Moreno C. Polypharmacy with antidepressants in children and adolescents. Int J Neuropsychopharmacology. 2014;17:1063\u201382.","journal-title":"Int J Neuropsychopharmacology"},{"key":"4321_CR43","unstructured":"Goldsmith SK, Pellmar TC, Kleinman AM, Bunney WE, editors. Reducing suicide: a national imperative. Washington, DC: National Academies Press; 2002."}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04321-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04321-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04321-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:02:16Z","timestamp":1792522936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04321-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4321"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-04321-x","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PGx testing as part of this study was performed by Gene S, an early-stage biotechnology company, which performed PGx testing free of charge as part of this research collaboration funded by the Western Australian State Government\u2019s Future Health and Innovation Fund, Innovation Challenge 2021: Child and Youth Mental Health program (IC2021\/14). The broader research team has no financial, commercial or consultative relationship with Gene S. One or more members of the Gene S team are included as co-authors on this paper. Their involvement was limited to the provision of testing kits, technical PGx analysis and PGx reports and contribution to sections of the manuscript describing the testing procedures. They had no input into the design of the study protocol, nor the analysis provided in this paper. Their inclusion as authors reflects their technical input and role in supporting implementation of the PGx component of this trial. All other authors have no competing interests to declare. Finally, all funders previously listed have had no role or influence on this paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"574"}}